ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
Analyst Upgrades and Downgrades
Separately, Aegis reaffirmed a "buy" rating on shares of ImmuCell in a research note on Thursday, June 23rd.
ImmuCell Stock Down 6.9 %
ICCC traded down $0.60 during trading hours on Monday, hitting $8.15. 3 shares of the company's stock were exchanged, compared to its average volume of 10,404. ImmuCell has a 12-month low of $7.30 and a 12-month high of $10.96. The firm has a 50 day moving average of $8.50 and a 200 day moving average of $8.64. The firm has a market cap of $63.11 million, a P/E ratio of 271.76 and a beta of 0.58. The company has a current ratio of 6.91, a quick ratio of 5.07 and a debt-to-equity ratio of 0.30.
ImmuCell (NASDAQ:ICCC - Get Rating) last announced its quarterly earnings data on Thursday, May 12th. The biotechnology company reported $0.09 EPS for the quarter. ImmuCell had a net margin of 1.34% and a return on equity of 0.84%. The company had revenue of $6.00 million for the quarter.